Issue No. 805 (dated 6/11/15) of the Medical Technology Stock Letter from BioInvest includes the Biotech Sector Analysis as well as updates from the following companies found in the MTSL Portfolio: #ANTH, #CBMG, #IMGN, #INCY, #ISIS, #MDCO, #NKTR, #OGXI, #ZIOP
Biotech buyout fever is going to continue. But be careful: You need to pick the right companies and hold them for years. Find out the reasons biotech buyouts will continue and stock picks from biotech analysts including John McCamant of BioInvest.
Medical Technology Stock Letter – Issue #802: Upgrading INCY & Time To Drink The Nektar
Guest John McCamant, editor of the Medical Technology Stock Letter (MTSL), joins Wide World of Stocks host Damon Roberts to discuss a potential biotech bubble, merger mania, and opportunity with ZIOPHARM (NASDAQ: ZIOP)
Issue No. 804 (dated 5/29/15) of the Medical Technology Stock Letter from BioInvest includes the Biotech Sector Analysis as well as updates from the following companies found in the MTSL Portfolio: #FPRX, #CBMG, #INCY and #OGXI
Gene Marcial of Forbes interviews John McCamant of the Medical Technology Stock Letter to discuss an attractive M&A play in the Biotech Space.
Medical Technology Stock Letter – Issue #801: Anthera Getting Clearer Tasting CHABLIS $ANTH
Special Update – The Medicines Company (MDCO) – Angiomax Pre-Announcement Now Discounts Patent Loss – The Reincarnation Is Around The Corner. Q1 Angiomax Shortfall Not Entirely Unexpected. In our last Issue, we mentioned that based upon the judge’s comments from the March trial, Hospira is very optimistic that they will win the Angiomax patent lawsuit. read more…
Issue No. 803 (dated 5/14/15) of the Medical Technology Stock Letter from BioInvest includes the Biotech Sector Analysis as well as updates from the following companies found in the MTSL Portfolio: #ACAD, #ISIS, #MDCO, #NVAX, #SGMO and #ZIOP
An immunotherapy revolution is rocking biotechnology, and investors are searching for just the right way to play the new trend. Do you go with an unknown company where the upside could be unparalleled? Do you go with an older name that has established partnerships with major pharmas? John McCamant, editor of the Medical Technology Stock Letter, has performed some serious diligence, and tells The Life Sciences Report about a handful of names with a range of market caps and the potential to achieve significant investment upside.
April 2 , 2015 Below is a pdf for Issue 800 of the Medical Technology Stock Letter. [gview file=http://www.bioinvest.com/wp-content/uploads/2015/04/MTSL-800-April-2-2015-final.pdf save=”1″]
Our guest today is Jay Silverman, a leading biotechnology sector analyst and editor of The Medical Technology Stock Letter. He updates us on the acquisition of one of his long-standing recommendations, the impact of this deal on the biotech space, and a trio of additional ideas for long-term investors to consider.
